4. What types of lesions cause MI ?
Coronary stenosis severity prior to MI
100 100
14%
80 80
Coronary stenosis (%)
18%
60 60 68%
40 40
20 20
0 0
Ambrose Little Nobuyoshi Giroud All four
1988 1988 1991 1992 studies
<50% 50%-70% >70%
Falk E, et al. Circulation. 1995;92:657-671.
www.drsarma.in 4
5. What types of lesions cause MI ?
Coronary stenosis severity prior to MI
100 100
14%
80 80
Coronary stenosis (%)
18%
60 60 68%
40 40
20 20
0 0
Ambrose Little Nobuyoshi Giroud All four
1988 1988 1991 1992 studies
<50% 50%-70% >70%
Falk E, et al. Circulation. 1995;92:657-671.
www.drsarma.in 5
6. CV Risk Factors in Diabetes
12
10.0
10
8
Odds Ratio
6.5
6
3.2
4
2.3
2
0
Microalbuminuria Smoking Diastolic BP Cholesterol
Eastman RC, Keen H. Lancet 1997;350 Suppl 1:29-32.
www.drsarma.in 6
10. Duration of T2DM and CVD
48%
29%
24%
21%
15%
≤2 3-5 6-9 10-14 15+
Years after DM Diagnosis
Harris, S et al.; Type 2 Diabetes and Associated Complications in Primary Care in
Canada: The Impact of Duration of Disease on Morbidity Load. CDA 2003.
www.drsarma.in 10
11. Duration of DM - CV Mortality
4 p for trend <0.001
3.5
Relative Risk
3
2.5
2
1.5
1
0.5
0
<5 6 to 10 11 to 15 16 to 25 26 +
Duration of Diabetes (years)
Cho, et al. J Am Coll Card 2002:40:954.
www.drsarma.in 11
12. Life Expectancy with Diabetes
Years
DM
90 No DM 1600
80 1400
70 1200
60 Diabetes
1000 No Diabetes
50
800
40
600
30
400
20
10 200
0 0
Men Women Mortality rate/100,000
Hux JE, et al. Diabetes in Ontario, an ICES Practice Atlas 2003.
www.drsarma.in 12
13. Cardiovascular Disease and T2DM
20%
Prevalence of CV Disease
Diabetes
15%
No Diabetes
10%
5%
0%
Hypertension Heart Disease
Hux JE, et al. Diabetes in Ontario, an ICES Practice Atlas 2003.
www.drsarma.in 13
14. Clinical Outcome for Diabetes
4-year Follow-up
14
12
10
8
%
6
4
2
0
CV Death MI Stroke Dialysis
HOPE / MICRO-HOPE. Lancet 2000;355:253.
www.drsarma.in 14
15. ACS and Diabetes – Up to 1 Year
25
P<0.0001
No Diabetes
20 21.3
% of patients
N = 3429
Diabetes P<0.0001
15 N = 1149
14.4 14.1
P=0.035
10
8.9 7.9
P<0.0001 7.
5 1
3.9
1.8
0
In-Hospital Non-fatal MI 1-y All-Cause 1-y
Mortality Mortality Mortality/MI
Yan R, et al. Can J Cardiol 2003;19(suppl A):260A.
www.drsarma.in 15
18. DM = CAD - Because
• CVD is responsible for 60 - 75% of mortality in T2DM
• CVD is 4 times more prevalent in diabetes; CADI is more
• CVD prevalence increases with age, so is T2DM
• CVD in DM is often severe, silent, poor prognosis and fatal
• Diabetes ↑ mortality, 50% pre adm / recurrent MI and ACS
• Diabetes erases the protection conferred to women
• At diagnosis of T2DM, most patients have evidence of CVD
• Abnormal Glucose tolerance is a strong CV Risk factor
www.drsarma.in 18
27. Dyslipidemia in DM and IRS
• Elevated total TG
• Reduced HDL
• Small, dense LDL
• ↑ HDL 3 and ↓ HDL1 and HDL 2
• LDL is not usually high
• Postprandial Hyper lipemia
www.drsarma.in 27
28. Dyslipidemia in DM and IRS
Increased Decreased
• Triglycerides • HDL
• VLDL • Apo A-I
• LDL, sLDL
• Apo B
www.drsarma.in 28
31. Mechanisms of DM Dyslipidemia
Fat Cells Liver
FFA
IR X
Insulin
www.drsarma.in 31
32. Mechanisms of DM Dyslipidemia
Fat Cells Liver
FFA
TG VLDL
Apo B
IR X VLDL
Insulin
www.drsarma.in 32
33. Mechanisms of DM Dyslipidemia
Fat Cells Liver
FFA CE
TG (hepatic
VLDL (CETP) HDL
Apo B lipase)
IR X VLDL TG
Apo A-1
Kidney
Insulin
www.drsarma.in 33
34. Mechanisms of DM Dyslipidemia
Fat Cells Liver
FFA CE
TG (hepatic
VLDL (CETP) HDL
Apo B lipase)
IR X VLDL TG
Apo A-1
CE (CETP) TG
Kidney
Insulin
SD
LDL
LDL
(lipoprotein or hepatic lipase)
www.drsarma.in 34
35. IR and TG Increase
625
r = 0.73
500 P < 0.0001
Plasma TG (mg/dL)
400
300
200
100
100 200 300 400 500 600
Insulin Response to Oral Glucose
Olefsky JM et al. Am J Med. 1974;57:551-560.
www.drsarma.in 35
36. DM, IRS and HDL
Hyperinsulinemic
P < 0.005
Normoinsulinemic
HDL-C (mg/dL)
P < 0.005
Non-obese Obese
Reaven GM. In: Le Roith D et al., eds. Diabetes Mellitus.1996:509-519.
www.drsarma.in 36
37. Effects of TG on CV Risk
• Accumulation of chylomicron remnants
• Accumulation of VLDL remnants
• Generation of small, dense LDL
• Association with low HDL
• Increased coagulability
• PAI-1, and factor VIIc
• Activation of prothrombin to thrombin
www.drsarma.in 37
38. Small Dense LDL and CHD
Potential Atherogenic Mechanisms
• Increased susceptibility to oxidation
• Increased vascular permeability
• Conformational change in Apo B
• ↓ Affinity for LDL receptor (↓ clearance)
• Association with insulin resistance syndrome
• Association with high TG and low HDL
Austin MA et al. Curr Opin Lipidol 1996;7:167-171.
www.drsarma.in 38
48. A A1c (Hb A1c)
B Blood pressure (goal)
C Cholesterol (all lipids)
www.drsarma.in 48
49. Ticking Clock of T2DM
1. Micro-vascular (DR, DKD, DPN, DAN)
At the onset of hyperglycemia
Control of hyperglycemia essential
The A1c target of less than 7 must (A)
1. Macro-vascular (CAD, CVD, PVD)
At the onset of insulin resistance
Blood pressure goal of 130/80 (B)
Control of lipid abnormalities (C)
www.drsarma.in 49
51. Goals inT2DM for VP
Risk Factor Goal or Target
Glycemia Hb A1c < 6.5%
Blood Pressure < 130/80 mm Hg
LDL target < 100 mg%; better < 70
HDL target > 40 men, > 50 women
TG target < 150 mg%
BMI < 25 kg/m2
Physical activity At least 5 days - 2 km/day
ADA, CDA, IDF, WWD
www.drsarma.in 51
52. From Blood Sugar to Blood Vessel
ACEi (Ramipril) Vasoprotective, anti HT, ↓ ED
ASA (75 to 150 mg%) Anti inflamm., Anti Platelet
Statin (Powerful, full) ↓ LDL, TG, Corrects ED, Inflam
BP Goal Vascular damage, LVH, CVA
Glycemic control ↓ Micro vascular ? Macrovascular
Physical activity ED, ↓ Inflammation, ↑ HDL
Diet and TLC ↓ TG, LDL, Glycemia, Weight
Smoking cessation ↓ ED and Inflammation
www.drsarma.in 52
53. ACEi in T2DM - VP
• Antihypertensive, vasoprotective, antithrombotic, and
anti-inflammatory properties – Inevitable in DM
• Reduce CV events, Reduce atherosclerosis
• Reduce renal disease which is a strong CV risk factor
• Metabolically ‘friendly’ drugs that prevent rises in glucose
& prevent diabetes
• Well-tolerated with few side effects
www.drsarma.in 53
55. MNT and Dyslipidemia
• Total CHO to be reduced < 50% of calories
• Saturated fat must reduced to< 7% of calories
• MUFA and PUFA up to 15% of calories
• Protein in take to be increased – 25% of cal.
• Dietary fiber > 20 g/day -Soy protein, Fenugreek
• Vegetables, Nuts and fruits must every day
www.drsarma.in 55
56. Priorities for Treatment
If all lipid values are normal
1. Lifestyle interventions (TLC)
MNT, Physical Activity, Weight and Waist reduction
1. Statin in a minimum dose of 10 mg o.d
2. Follow up every one year by full lipid profile
3. All Indians must be tested for LP(a) and
If > 30 mg% - Niacin SR 350 to 500 mg started
www.drsarma.in 56
57. Priorities for Treatment
LDL cholesterol lowering – First priority
1. Lifestyle interventions (TLC)
2. Drugs - First choice – Statin with or without
3. Cholesterol absorption inhibitors (EZ)
4. Second choice – Niacin and Fibrate
5. Add on – BAR (Bile acid binding resins)
www.drsarma.in 57
58. Priorities for Treatment
HDL cholesterol raising – Second priority
1. Lifestyle interventions
2. First choice - Niacin ( doses <2 g/day)
3. Preferably short acting Niacin
4. Fibrates are second choice
www.drsarma.in 58
59. Priorities for Treatment
Triglyceride lowering – Third priority
1. First choice: Lifestyle interventions
2. Glycemic control is the best Rx for ↓TG
3. Fibrates
4. Niacin
5. High dose statins (if LDL is also high )
www.drsarma.in 59
60. Priorities for Treatment
Triglyceride Lowering (continued)
• In case of severe hyper triglyceridemia (> 1000 mg),
severe fat restriction (< 10 % of calories ) in
addition to pharmacological therapy is necessary to
reduce the risk of pancreatitis and lipemia effects
www.drsarma.in 60
61. Priorities for Treatment
Combined Dyslipidemia
1. First choice: Glycemic control + Statin
2. Glycemic control+ Statin + Fibrate
3. Glycemic control+ Statin + Niacin
www.drsarma.in 61
62. Drug Rx. – Effect on Lipoproteins
ADA. Diabetes Care 2003;26 (suppl 1):S 83-S 86
www.drsarma.in 62
70. To Reiterate
Glycemic goal alone is not adequate at all
CAD must be prevented at all costs
The A, B, C of Diabetes must be addressed
Statins in full dose ± Fibrate or Niacin
All T2DM must receive drugs/advise on
ACEi/ARB, ASA, Statin, TLC, PA, ↓ Weight
www.drsarma.in 70